PFIZER’S COVID-19 PILL FAILS TO PREVENT SYMPTOMATIC INFECTIONS
Sat 30 April 2022: Pfizer said Friday that results from a study, which evaluated the Paxlovid for post-exposure preventive use, were not statistically significant. The primary endpoint of reducing the risk of confirmed and symptomatic Covid-19 infection in adults who had been exposed to the virus through a household contact was not met in the study. The analysis evaluated data […]
Continue Reading
